Evidence map›Paper›PMID 33145409›Full record

ArticleACS central science2020

Elevated Vacuolar Uptake of Fluorescently Labeled Antifungal Drug Caspofungin Predicts Echinocandin Resistance in Pathogenic Yeast.

Qais Z Jaber, Maayan Bibi, Ewa Ksiezopolska, Toni Gabaldon, Judith Berman, Micha Fridman

Abstract read
In one paragraph

Article in ACS central science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The cellular model for Alzheimer's disease research: PC12 cells.Frontiers in molecular neuroscience · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Mitochondrial cardiolipin sequestration of caspofungin underliesbioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Low-level direct currents eradicate multi-drug-resistantChemical engineering journal (Lausanne, Switzerland : 1996) · 2025
    Article
  9. Article
  10. Article
  11. Echinocandins - structure, mechanism of action and use in antifungal therapy.Journal of enzyme inhibition and medicinal chemistry · 2022
    Review
  12. Caspofungin resistance in Candida albicans: genetic factors and synergistic compounds for combination therapies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qais Z JaberSchool of Chemistry, Raymond & Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Maayan BibiSchool of Molecular Cell Biology and Biotechnology, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Ewa KsiezopolskaBarcelona Supercomputing Centre (BSC-CNS) Jordi Girona, 29, Barcelona 08034, Spain.
Toni GabaldonBarcelona Supercomputing Centre (BSC-CNS) Jordi Girona, 29, Barcelona 08034, Spain.
Judith BermanSchool of Molecular Cell Biology and Biotechnology, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Micha FridmanSchool of Chemistry, Raymond & Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Echinocandins are the newest class of antifungal drugs in clinical use. These agents inhibit β-glucan synthase, which catalyzes the synthesis of β-glucan, an essential component of the fungal cell wall, and have a high clinical efficacy and low toxicity. Echinocandin resistance is largely due to mutations in the gene encoding β-glucan synthase, but the mode of action is not fully understood. We developed fluorescent probes based on caspofungin, the first clinically approved echinocandin, and studied their cellular biology in

Identifiers

PMID33145409
PMCPMC7596861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.